FORMULATION FOR ANTI-α4β7 ANTIBODY

• Main Authors: ERICA HELEN JENKINS, IRVING H FOX, CSANAD M VARGA, VAITHIANATHAN PALANIAPPAN, MARIA ROSARIO, CATHERINE SCHOLZ, WILLOW DILUZIO, PHUONG M NGUYEN, JASON BROWN
• Format: Patent
• Language: English; Japanese
• Published: 04.04.2019
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

To provide a formulation for an anti-α4β7 antibody.SOLUTION: There is provided a pharmaceutical composition for treating inflammatory bowel disease in a human patient. The composition comprises a humanized anti-α4β7 antibody comprising: a heavy chain variable region comprising complementarity determining region 1 (CDR1) represented by SEQ ID NO:8, CDR2 represented by SEQ ID NO:9, and CDR3 represented by SEQ ID NO:10; and a light chain variable region comprising CDR1 represented by SEQ ID NO:11, CDR2 represented by SEQ ID NO:12, and CDR3 represented by SEQ ID NO:13. The antibody is subcutaneously administered at a dose of 108 mg to the human patient every two weeks.SELECTED DRAWING: None 【課題】抗α４β７抗体のための製剤を提供すること。【解決手段】ヒト患者における炎症性大腸疾患を治療するための医薬組成物であって、該組成物は、配列番号８で示される相補性決定領域１（ＣＤＲ１）、配列番号９で示されるＣＤＲ２及び配列番号１０で示されるＣＤＲ３を含む重鎖可変領域、並びに配列番号１１で示されるＣＤＲ１、配列番号１２で示されるＣＤＲ２及び配列番号１３で示されるＣＤＲ３を含む軽鎖可変領域を含むヒト化抗α４β７抗体を含み、該抗体は、２週間ごとに、ヒト患者に１０８ｍｇの用量で皮下投与されるものである、医薬組成物。【選択図】なし